Ajinomoto acquires Norgine product for Japan
This article was originally published in Scrip
Norginehas granted Ajinomotoexclusive Japanese development, manufacturing and marketing rights to its prescription bowel cleansing product Moviprep. Financial details of the transaction, Norgine's first for the Japanese market, were not disclosed. The product is used prior to colonoscopy and other procedures and is already marketed by Norgine in Europe and Salix Pharmaceuticals in the US. Ajinomoto, a diversified foods group, already markets a similar intestinal cleansing solution, Niflec, in its home market.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.